Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
National Bank of Canada FI Has $46,000 Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
05:06am, Monday, 20'th May 2024
National Bank of Canada FI cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 99.0% in the fourth quarter, according to the company in its most recent filing with the Secu
3 Monster Stocks in the Making You Can Buy Right Now
06:47am, Saturday, 18'th May 2024
Altimmune could have a blockbuster weight-loss drug on the way. Axsome Therapeutics has two products on the market plus multiple promising-pipeline programs.
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
10:00am, Saturday, 11'th May 2024
The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for
Prediction: These 2 Growth Stocks Could Triple By 2030
09:00am, Saturday, 11'th May 2024
Axsome Therapeutics is a small biotech quickly making clinical progress. Shopify is riding the wave of the rapidly growing e-commerce market.
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
04:36am, Friday, 10'th May 2024
Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders. The company has a diverse pipeline tar
Axsome Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 08'th May 2024
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
12:31pm, Tuesday, 07'th May 2024
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 06'th May 2024
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
09:31am, Friday, 03'rd May 2024
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
07:00am, Wednesday, 01'st May 2024
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
03:20pm, Tuesday, 30'th Apr 2024
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
11:06am, Monday, 29'th Apr 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
01:17pm, Tuesday, 16'th Apr 2024
Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achiev
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
07:00am, Monday, 15'th Apr 2024
AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting ef
